UK health authorities have approved an updated version of the Moderna company's Covid-19 vaccine specifically designed to counter the Omicron variant, as well as the original form of the virus.
The National Medicines Agency (MHRA) said in a statement that it had approved the vaccine for booster doses for adults "after it was found to comply with UK regulatory safety , quality and efficacy standards" and in capable of eliciting a "strong immune response" against both strains.
IN EUROPE - Meanwhile, even in Europe, the wait for vaccines against the latest coronavirus variants is about to end, with the European Commission working tirelessly to be ready for the cold season , when the curve could raise its head.
The first doses of the vaccines adapted to the BA.4 and BA.5 Omicron variants have already been booked, although the authorization of the European Medicines Agency (EMA) is required first, whose lens is, since mid-June, aimed at updating the immunizers intended to target both the original SarsCoV2 strain and subsequent subtypes.
Brussels has also closed an agreement with the American company Moderna to once again adjust its delivery calendar , postponing the supply of the lots initially planned for the summer to September and during the autumn-winter. An agreement that will ensure that "countries have access to the doses they need at the right time to protect their citizens", explained the European Commissioner for Health, Stella Kyriakides. And, above all, which ensures the first 15 million doses adapted to the variants to the European capitals.
